PARP inhibitors have been approved for the treatment of several cancers, including ovarian, breast, pancreatic and prostate cancers with BRCA mutations or other homologous recombination repair ...

this time in first-line treatment of advanced ovarian cancer. Results from the PAOLA-1 study showed that the PARP inhibitor drug significantly increased the time women lived without disease ...

Impact Therapeutics Inc. has synthesized poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of neurologic cancer.

Cells have another protein called PARP1 [poly(ADP-ribose) polymerase 1] that flags ... a class of drugs known as PARP inhibitors has been shown to help many BRCA2-deficient cancer patients achieve ...

They are only used if the cancer has specific characteristics. Poly (ADP-ribose) polymerase (PARP) inhibitors: These are used for people whose prostate cancer cells have mutations in certain genes, ...

Positive results of PARP inhibitor and CAR T-cell treatments highlight advances in research for neuroblastoma.

Pfizer has won FDA approval for its PARP inhibitor Talzenna in castration-resistant prostate cancer (CRPC ... new indication is the key to unlocking $1 billion in annual revenues for Talzenna ...

A phase 1b/2 trial in triple-negative breast cancer will assess LP-184 alone and with a PARP inhibitor in advanced cases.

A 2023 study published in the Journal of the American Medical Association found that only 6.8% of more than 1 million ... cancer patients have a genetic predisposition and qualify for a PARP ...